메뉴 건너뛰기




Volumn 58, Issue , 2007, Pages 347-358

T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and transplantation

Author keywords

Abatacept; Belatacept; Rheumatoid arthritis; Transplantation

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTILIPEMIC AGENT; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; EVEROLIMUS; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN;

EID: 34047186008     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.58.080205.154004     Document Type: Review
Times cited : (60)

References (54)
  • 1
    • 0033524482 scopus 로고    scopus 로고
    • A two-step, two-signal model for the primary activation of precursor helper T cells
    • Bretscher PA. 1999. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc. Natl. Acad. Sci. USA 96(1):185-90
    • (1999) Proc. Natl. Acad. Sci. USA , vol.96 , Issue.1 , pp. 185-190
    • Bretscher, P.A.1
  • 2
    • 0032502801 scopus 로고    scopus 로고
    • Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
    • Van Parijs L, Abbas AK. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280(5361):243-48
    • (1998) Science , vol.280 , Issue.5361 , pp. 243-248
    • Van Parijs, L.1    Abbas, A.K.2
  • 3
    • 0036156661 scopus 로고    scopus 로고
    • The role of novel T cell costimulatory pathways in autoimmunity and transplantation
    • Yamada A, Salama AD, Sayegh MH. 2002. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13(2):559-75
    • (2002) J. Am. Soc. Nephrol , vol.13 , Issue.2 , pp. 559-575
    • Yamada, A.1    Salama, A.D.2    Sayegh, M.H.3
  • 4
    • 0032543306 scopus 로고    scopus 로고
    • The role of T-cell costimulatory activation pathways in transplant rejection
    • Sayegh MH, Turka LA. 1998. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338(25):1813-21
    • (1998) N. Engl. J. Med , vol.338 , Issue.25 , pp. 1813-1821
    • Sayegh, M.H.1    Turka, L.A.2
  • 5
    • 0032996025 scopus 로고    scopus 로고
    • Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
    • Kirk AD, Burkly LC, Batty DS, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5(6):686-93
    • (1999) Nat. Med , vol.5 , Issue.6 , pp. 686-693
    • Kirk, A.D.1    Burkly, L.C.2    Batty, D.S.3
  • 6
    • 0036130828 scopus 로고    scopus 로고
    • CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism
    • Andre P, Prasad KS, Denis CV, et al. 2002. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat. Med. 8(3):247-52
    • (2002) Nat. Med , vol.8 , Issue.3 , pp. 247-252
    • Andre, P.1    Prasad, K.S.2    Denis, C.V.3
  • 7
    • 0027403299 scopus 로고
    • The role of the CD28 receptor during T cell responses to antigen
    • Linsley PS, Ledbetter JA. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191-212
    • (1993) Annu. Rev. Immunol , vol.11 , pp. 191-212
    • Linsley, P.S.1    Ledbetter, J.A.2
  • 10
    • 0035101515 scopus 로고    scopus 로고
    • CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis
    • Kim KS, Denton MD, Chandraker A, et al. 2001. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158(3):977-86
    • (2001) Am. J. Pathol , vol.158 , Issue.3 , pp. 977-986
    • Kim, K.S.1    Denton, M.D.2    Chandraker, A.3
  • 11
    • 0026486220 scopus 로고
    • Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
    • Linsley PS, Greene JL, Tan P, et al. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176(6):1595-604
    • (1992) J. Exp. Med , vol.176 , Issue.6 , pp. 1595-1604
    • Linsley, P.S.1    Greene, J.L.2    Tan, P.3
  • 12
    • 0027937702 scopus 로고
    • Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
    • Peach RJ, Bajorath J, Brady W, et al. 1994. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180(6):2049-58
    • (1994) J. Exp. Med , vol.180 , Issue.6 , pp. 2049-2058
    • Peach, R.J.1    Bajorath, J.2    Brady, W.3
  • 13
    • 0028675006 scopus 로고
    • Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
    • Linsley PS, Greene JL, Brady W, et al. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1(9):793-801
    • (1994) Immunity , vol.1 , Issue.9 , pp. 793-801
    • Linsley, P.S.1    Greene, J.L.2    Brady, W.3
  • 14
    • 0029914089 scopus 로고    scopus 로고
    • Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions
    • Greene JL, Leytze GM, Emswiler J, et al. 1996. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271(43):26762-71
    • (1996) J. Biol. Chem , vol.271 , Issue.43 , pp. 26762-26771
    • Greene, J.L.1    Leytze, G.M.2    Emswiler, J.3
  • 16
    • 4444369694 scopus 로고    scopus 로고
    • B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
    • Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. 2004. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21(3):401-13
    • (2004) Immunity , vol.21 , Issue.3 , pp. 401-413
    • Pentcheva-Hoang, T.1    Egen, J.G.2    Wojnoonski, K.3    Allison, J.P.4
  • 18
    • 0026738641 scopus 로고
    • Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg
    • Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257(5071):789-92
    • (1992) Science , vol.257 , Issue.5071 , pp. 789-792
    • Lenschow, D.J.1    Zeng, Y.2    Thistlethwaite, J.R.3
  • 19
    • 0028365181 scopus 로고
    • Transplantation tolerance induced by CTLA4-Ig
    • Pearson TC, Alexander DZ, Winn KJ, et al. 1994. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57(12):1701-6
    • (1994) Transplantation , vol.57 , Issue.12 , pp. 1701-1706
    • Pearson, T.C.1    Alexander, D.Z.2    Winn, K.J.3
  • 20
    • 20044386299 scopus 로고    scopus 로고
    • Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties
    • Larsen CP, Pearson TC, Adams AB, et al. 2005. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3):443-53
    • (2005) Am. J. Transplant , vol.5 , Issue.3 , pp. 443-453
    • Larsen, C.P.1    Pearson, T.C.2    Adams, A.B.3
  • 21
    • 0029849012 scopus 로고    scopus 로고
    • Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: Requirement for both B7-1 and B7-2
    • Webb LM, Walmsley MJ, Feldmann M. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26(10):2320-28
    • (1996) Eur. J. Immunol , vol.26 , Issue.10 , pp. 2320-2328
    • Webb, L.M.1    Walmsley, M.J.2    Feldmann, M.3
  • 22
    • 0028483990 scopus 로고
    • Treatment of murine lupus with CTLA4Ig
    • Finck BK, Linsley PS, Wofsy D. 1994. Treatment of murine lupus with CTLA4Ig. Science 265(5176):1225-27
    • (1994) Science , vol.265 , Issue.5176 , pp. 1225-1227
    • Finck, B.K.1    Linsley, P.S.2    Wofsy, D.3
  • 23
    • 0028800090 scopus 로고
    • The epidemiology of drug treatment failure in rheumatoid arthritis
    • Wolfe F. 1995. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin. Rheumatol. 9(4):619-32
    • (1995) Baillieres Clin. Rheumatol , vol.9 , Issue.4 , pp. 619-632
    • Wolfe, F.1
  • 24
    • 0035883897 scopus 로고    scopus 로고
    • Rheumatoid arthritis
    • Lee DM, Weinblatt ME. 2001. Rheumatoid arthritis. Lancet 358(9285):903-11
    • (2001) Lancet , vol.358 , Issue.9285 , pp. 903-911
    • Lee, D.M.1    Weinblatt, M.E.2
  • 25
    • 0020039524 scopus 로고
    • Augmented numbers of HLA-DR-positive T lymphocytes in the synovial fluid and synovial tissue of patients with rheumatoid arthritis and juvenile rheumatoid arthritis: In vivo-activated T lymphocytes are potent stimulators in the mixed lymphocyte reaction
    • Forre O, Dobloug JH, Natvig JB. 1982. Augmented numbers of HLA-DR-positive T lymphocytes in the synovial fluid and synovial tissue of patients with rheumatoid arthritis and juvenile rheumatoid arthritis: in vivo-activated T lymphocytes are potent stimulators in the mixed lymphocyte reaction. Scand J. Immunol. 15(2):227-31
    • (1982) Scand J. Immunol , vol.15 , Issue.2 , pp. 227-231
    • Forre, O.1    Dobloug, J.H.2    Natvig, J.B.3
  • 26
    • 0019411775 scopus 로고
    • Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates
    • Konttinen YT, Reitamo S, Ranki A, et al. 1981. Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates. Arthritis Rheum. 24(1):71-79
    • (1981) Arthritis Rheum , vol.24 , Issue.1 , pp. 71-79
    • Konttinen, Y.T.1    Reitamo, S.2    Ranki, A.3
  • 27
    • 0141427819 scopus 로고    scopus 로고
    • Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: A matched observational study
    • Aletaha D, Stamm T, Kapral T, et al. 2003. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann. Rheum. Dis. 62(10):944-51
    • (2003) Ann. Rheum. Dis , vol.62 , Issue.10 , pp. 944-951
    • Aletaha, D.1    Stamm, T.2    Kapral, T.3
  • 28
    • 19044375758 scopus 로고    scopus 로고
    • Effective use of TNF antagonists
    • Yocum D. 2004. Effective use of TNF antagonists. Arthritis Res. Ther. 6 (Suppl. 2):S24-30
    • (2004) Arthritis Res. Ther , vol.6 , Issue.SUPPL. 2
    • Yocum, D.1
  • 29
    • 10944261085 scopus 로고    scopus 로고
    • Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
    • Schwartzman S, Fleischmann R, Morgan GJ Jr. 2004. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res. Ther. 6 (Suppl. 2):S3-S11
    • (2004) Arthritis Res. Ther , vol.6 , Issue.SUPPL. 2
    • Schwartzman, S.1    Fleischmann, R.2    Morgan Jr., G.J.3
  • 30
    • 0012469264 scopus 로고    scopus 로고
    • United States Food and Drug Administration, Americans with Disabilities Act Committee, Accessed Sep. 7
    • United States Food and Drug Administration, Americans with Disabilities Act Committee. 2006. Safety update on TNF antagonists: infliximab and etanercept. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2.htm. Accessed Sep. 7, 2006
    • (2006) Safety update on TNF antagonists: Infliximab and etanercept
  • 31
    • 1642540027 scopus 로고    scopus 로고
    • Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: Dose adjustments are common but not always sufficient to assure sustained benefit
    • Sidiropoulos P, Bertsias G, Kritikos HD, et al. 2004. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann. Rheum. Dis. 63(2):144-48
    • (2004) Ann. Rheum. Dis , vol.63 , Issue.2 , pp. 144-148
    • Sidiropoulos, P.1    Bertsias, G.2    Kritikos, H.D.3
  • 32
    • 0033135564 scopus 로고    scopus 로고
    • CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
    • Abrams JR, Lebwohl MG, Guzzo CA, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103(9):1243-52
    • (1999) J. Clin. Invest , vol.103 , Issue.9 , pp. 1243-1252
    • Abrams, J.R.1    Lebwohl, M.G.2    Guzzo, C.A.3
  • 33
    • 23644455857 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial
    • Kremer JM, Dougados M, Emery P, et al. 2005. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(8):2263-71
    • (2005) Arthritis Rheum , vol.52 , Issue.8 , pp. 2263-2271
    • Kremer, J.M.1    Dougados, M.2    Emery, P.3
  • 34
    • 0242574700 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
    • Kremer JM, Westhovens R, Leon M, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20):1907-15
    • (2003) N. Engl. J. Med , vol.349 , Issue.20 , pp. 1907-1915
    • Kremer, J.M.1    Westhovens, R.2    Leon, M.3
  • 35
    • 33745291091 scopus 로고    scopus 로고
    • Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial
    • Kremer JM, Genant HK, Moreland LW, et al. 2006. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12):865-76
    • (2006) Ann. Intern. Med , vol.144 , Issue.12 , pp. 865-876
    • Kremer, J.M.1    Genant, H.K.2    Moreland, L.W.3
  • 36
    • 34248159251 scopus 로고    scopus 로고
    • Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis patients with inadequate responses to methotrexate
    • Abstr. SAT0203
    • Westhovens R, Emery P, Aranda R, et al. 2006. Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis patients with inadequate responses to methotrexate. Ann. Rheum. Dis. 65(Suppl. II):512, Abstr. SAT0203
    • (2006) Ann. Rheum. Dis , vol.65 , Issue.SUPPL. II , pp. 512
    • Westhovens, R.1    Emery, P.2    Aranda, R.3
  • 37
    • 34248187386 scopus 로고    scopus 로고
    • Genant HK, Peterfy C, Wu C, et al. 2005. An ACR 20 response is not required for inhibition of structural damage progression by abatacept: results from the AIM Trial. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 1991
    • Genant HK, Peterfy C, Wu C, et al. 2005. An ACR 20 response is not required for inhibition of structural damage progression by abatacept: results from the AIM Trial. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 1991
  • 38
    • 33750992180 scopus 로고    scopus 로고
    • Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis
    • Weisman MH, Durez P, Hallegua D, et al. 2006. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. 33:2162-66
    • (2006) J. Rheumatol , vol.33 , pp. 2162-2166
    • Weisman, M.H.1    Durez, P.2    Hallegua, D.3
  • 39
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    • Genovese M, Becker J-C, Schiff M, et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11):1114-23
    • (2005) N. Engl. J. Med , vol.353 , Issue.11 , pp. 1114-1123
    • Genovese, M.1    Becker, J.-C.2    Schiff, M.3
  • 40
    • 33749365296 scopus 로고    scopus 로고
    • Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study
    • Weinblatt ME, Combe B, Covucci A, et al. 2006. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Res. 54:2807-16
    • (2006) Arthritis Res , vol.54 , pp. 2807-2816
    • Weinblatt, M.E.1    Combe, B.2    Covucci, A.3
  • 41
    • 34248204412 scopus 로고    scopus 로고
    • Moreland LW, Combe B, Steinfeld SD, et al. 2005. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 886
    • Moreland LW, Combe B, Steinfeld SD, et al. 2005. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 886
  • 42
    • 34248148394 scopus 로고    scopus 로고
    • UNOS
    • UNOS. 2006. http://www.unos.org/
    • (2006)
  • 43
    • 0042360213 scopus 로고    scopus 로고
    • Chronic renal failure after transplantation of a nonrenal organ
    • Ojo AO, Held PJ, Port FK, et al. 2003. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349(10):931-40
    • (2003) N. Engl. J. Med , vol.349 , Issue.10 , pp. 931-940
    • Ojo, A.O.1    Held, P.J.2    Port, F.K.3
  • 44
    • 0031586439 scopus 로고    scopus 로고
    • Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group
    • Nashan B, Moore R, Amlot P, et al. 1997. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350(9086):1193-98
    • (1997) Lancet , vol.350 , Issue.9086 , pp. 1193-1198
    • Nashan, B.1    Moore, R.2    Amlot, P.3
  • 45
    • 12644262358 scopus 로고    scopus 로고
    • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
    • Kirk AD, Harlan DM, Armstrong NN, et al. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94(16):8789-94
    • (1997) Proc. Natl. Acad. Sci. USA , vol.94 , Issue.16 , pp. 8789-8794
    • Kirk, A.D.1    Harlan, D.M.2    Armstrong, N.N.3
  • 46
    • 0031307384 scopus 로고    scopus 로고
    • Immunosuppressive effects of human CTLA4Ig in a nonhuman primate model of allogeneic pancreatic islet transplantation
    • Levisetti MG, Padrid PA, Szot GL, et al. 1997. Immunosuppressive effects of human CTLA4Ig in a nonhuman primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159(11):5187-91
    • (1997) J. Immunol , vol.159 , Issue.11 , pp. 5187-5191
    • Levisetti, M.G.1    Padrid, P.A.2    Szot, G.L.3
  • 48
    • 0028826268 scopus 로고
    • Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies
    • Lenschow DJ, Zeng Y, Hathcock KS, et al. 1995. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 60(10):1171-78
    • (1995) Transplantation , vol.60 , Issue.10 , pp. 1171-1178
    • Lenschow, D.J.1    Zeng, Y.2    Hathcock, K.S.3
  • 49
    • 20044386299 scopus 로고    scopus 로고
    • Rational development of LEA29Y, a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties
    • Larsen CP, Pearson TC, Adams AB, et al. 2005. Rational development of LEA29Y, a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3)443-53
    • (2005) Am. J. Transplant , vol.5 , Issue.3 , pp. 443-453
    • Larsen, C.P.1    Pearson, T.C.2    Adams, A.B.3
  • 50
    • 23944502334 scopus 로고    scopus 로고
    • Costimulation blockade with belatacept in renal transplantation
    • Vincenti F, Larsen C, Durrbach A, et al. 2005. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8):770-81
    • (2005) N. Engl. J. Med , vol.353 , Issue.8 , pp. 770-781
    • Vincenti, F.1    Larsen, C.2    Durrbach, A.3
  • 51
    • 0036314948 scopus 로고    scopus 로고
    • Post-transplant renal function in the first year predicts long-term kidney transplant survival
    • Hariharan S, McBride MA, Cherikh WS, et al. 2002. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 62(1):311-18
    • (2002) Kidney Int , vol.62 , Issue.1 , pp. 311-318
    • Hariharan, S.1    McBride, M.A.2    Cherikh, W.S.3
  • 52
    • 4143127834 scopus 로고    scopus 로고
    • Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology
    • Nankivell BJ, Borrows RJ, Fung CL, et al. 2004. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78(4):557-65
    • (2004) Transplantation , vol.78 , Issue.4 , pp. 557-565
    • Nankivell, B.J.1    Borrows, R.J.2    Fung, C.L.3
  • 53
    • 16444362802 scopus 로고    scopus 로고
    • Combating chronic renal allograft dysfunction: Optimal immunosuppressive regimens
    • Merville P. 2005. Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 65(5):615-31
    • (2005) Drugs , vol.65 , Issue.5 , pp. 615-631
    • Merville, P.1
  • 54
    • 0036766652 scopus 로고    scopus 로고
    • Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor
    • Rosengard BR, Feng S, Alfrey EJ, et al. 2002. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am. J. Transplant. 2(8):701-11
    • (2002) Am. J. Transplant , vol.2 , Issue.8 , pp. 701-711
    • Rosengard, B.R.1    Feng, S.2    Alfrey, E.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.